Accelerated single cell seeding in relapsed multiple myeloma

Heather Landau(Memorial Sloan Kettering Cancer Center), Venkata D. Yellapantula(Memorial Sloan Kettering Cancer Center), Benjamin Diamond(Memorial Sloan Kettering Cancer Center), Even H. Rustad(Memorial Sloan Kettering Cancer Center), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), Gunes Gundem(Memorial Sloan Kettering Cancer Center), Juan S. Medina-Martínez(Memorial Sloan Kettering Cancer Center), Juan Arango Ossa(Memorial Sloan Kettering Cancer Center), Max F. Levine(Memorial Sloan Kettering Cancer Center), Yangyu Zhou(Memorial Sloan Kettering Cancer Center), Rajya Kappagantula(Memorial Sloan Kettering Cancer Center), Priscilla Baez(Memorial Sloan Kettering Cancer Center), Marc A. Attiyeh(Memorial Sloan Kettering Cancer Center), Alvin P. Makohon-Moore(Memorial Sloan Kettering Cancer Center), Lance Zhang(Memorial Sloan Kettering Cancer Center), Eileen M. Boyle(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Cody Ashby(University of Arkansas for Medical Sciences), Patrick Blaney(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Minal Patel(Memorial Sloan Kettering Cancer Center), Yanming Zhang(Memorial Sloan Kettering Cancer Center), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), David J. Chung(Memorial Sloan Kettering Cancer Center), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Oscar Lahoud(Memorial Sloan Kettering Cancer Center), Jonathan U. Peled(Memorial Sloan Kettering Cancer Center), Michael Scordo(Memorial Sloan Kettering Cancer Center), Gunjan L. Shah(Memorial Sloan Kettering Cancer Center), Hani Hassoun(Memorial Sloan Kettering Cancer Center), Neha Korde(Memorial Sloan Kettering Cancer Center), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Sydney X. Lu(Memorial Sloan Kettering Cancer Center), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Urvi A. Shah(Memorial Sloan Kettering Cancer Center), Eric L. Smith(Memorial Sloan Kettering Cancer Center), Malin Hultcrantz(Memorial Sloan Kettering Cancer Center), Gary A. Ulaner(Memorial Sloan Kettering Cancer Center), Frits van Rhee(University of Arkansas for Medical Sciences), Gareth J. Morgan(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Ola Landgren(Memorial Sloan Kettering Cancer Center), Elli Papaemmanuil(Memorial Sloan Kettering Cancer Center), Christine A. Iacobuzio–Donahue(Memorial Sloan Kettering Cancer Center), Francesco Maura(Memorial Sloan Kettering Cancer Center)
Nature Communications
July 17, 2020
Cited by 80Open Access
Full Text

Abstract

Multiple myeloma (MM) progression is characterized by the seeding of cancer cells in different anatomic sites. To characterize this evolutionary process, we interrogated, by whole genome sequencing, 25 samples collected at autopsy from 4 patients with relapsed MM and an additional set of 125 whole exomes collected from 51 patients. Mutational signatures analysis showed how cytotoxic agents introduce hundreds of unique mutations in each surviving cancer cell, detectable by bulk sequencing only in cases of clonal expansion of a single cancer cell bearing the mutational signature. Thus, a unique, single-cell genomic barcode can link chemotherapy exposure to a discrete time window in a patient's life. We leveraged this concept to show that MM systemic seeding is accelerated at relapse and appears to be driven by the survival and subsequent expansion of a single myeloma cell following treatment with high-dose melphalan therapy and autologous stem cell transplant.


Related Papers